HRSA’s Revised 340B Rebate Pilot Explained: What Claims-Based Rebates on 25 Negotiated Drugs Actually Change for Hospitals, Manufacturers, and TPAs, and Whether It Fixes 340B Transparency
🎧 Podcast episode for paid subscribers only. Also available on Spotify.
To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
Table of Contents
What HRSA actually did on August 3 and why the second try looks different from the first
The mechanics: WAC up front, 45 days to submit, 10 days to pay, and who eats the platform bill
Which 25 drugs, which 13 manufacturers, and why less than 5.5 percent of sales is the whole ballgame
The float, with actual arithmetic
Administrative burden, or how 34,320 dollars a year became a billion depending on who holds the calculator
The transparency question: does claims-level data fix what has bugged 340B for a decade
Duplicate discounts, nonduplication, and the MFP stacking problem actually driving this
No categorical exemptions, and what that means for CAHs, FQHCs, and rural referral centers
The legal posture: notice versus rule, the Maine vacatur, and the D.C. Circuit gift
The parallel squeeze: ASP minus 33.4 percent, accelerated clawback, and contract pharmacy litigation
Who builds the pipes, and why the infrastructure outlives the pilot
What to watch between now and April 30, 2028
Abstract
HRSA published a revised 340B Rebate Model Pilot Program in the Federal Register on Aug 3, 2026 (FR Doc 2026-15633), effective immediately, as a Notice rather than an NPRM. No new comment period.
Scope: NDC-11s of drugs on the Medicare Drug Price Negotiation Selected Drug Lists for initial price applicability years 2026 and 2027. Roughly 25 products from 13 manufacturers, up from 10 and 8 in the vacated 2025 version. All payers, all indications.
Mechanics: covered entity buys at WAC, submits claims-level data within 45 days of dispense, manufacturer pays or issues a documented denial within 10 days. Rebate equals WAC minus 340B ceiling price on date of dispense. Manufacturer funds the platform.
Timeline: plans due Aug 24, 2026. HRSA approvals by Sept 24. Minimum 90 days notice to covered entities. Go-live Jan 1, 2027. One-year minimum commitment. HRSA evaluation targeted for Apr 30, 2028.
Scale: HRSA pegs the affected products at under 5.5 percent of 2025 340B sales, against a program that grew from 53.7B in 2022 to over 100B in 2025.
Burden fight: HRSA estimates 523.3M dollars annually across 15,249 covered entities (about 34,320 each). AHA says north of 1B for hospitals alone, 150K to 500K+ per hospital.
Legal: the 2025 pilot was enjoined in D. Me. and vacated on remand. Novartis v. Kennedy (D.C. Cir., July 21, 2026) held Section 340B permits rebates but requires Secretarial authorization first, which strengthens HRSA’s hand while leaving APA process risk fully live.
Context: CY2027 OPPS proposes 340B reimbursement at ASP minus 33.4 percent and accelerates the conversion factor clawback to 3 percent annually through 2029.
What HRSA actually did on August 3 and why the second try looks different from the first
Round one of this thing died on the operating table. HRSA put out a rebate pilot notice on July 31, 2025, ran an absurdly compressed application window, approved nine manufacturer models by October 30, blessed Novartis shortly after, and then watched a federal judge in Maine blow the whole thing up on December 29, days before the January 1, 2026 launch. The First Circuit declined to stay the order on January 7. HHS eventually dropped the appeal, the Maine court vacated the pilot and the manufacturer approvals along with it, and by February HRSA was back at square one with a Request for Information instead of a program.
Round two arrived July 31, 2026 as an announcement and hit the Federal Register on August 3 as a 64-page Notice. The single most important structural fact about it is that it is not a proposed rule. There is no regulatory text, no proposed CFR amendment, no new comment window, and no comment deadline. It states that it is effective immediately upon publication unless a future notice revises it. HRSA’s position is that the deliberative process already happened: a February 17, 2026 RFI, a comment period that closed April 20, and 2,475 total submissions, of which 2,449 were public and 26 were not. A separate Paperwork Reduction Act information collection request ran its own 30-day clock that closed July 15, but that was about burden estimates, not underlying policy.
So the agency’s theory is roughly: the courts said the first attempt was procedurally sloppy, therefore build a record, respond to the record in writing, and issue the thing as an operative notice. Whether that survives contact with a judge is section nine’s problem.
What changed on substance is more interesting than the packaging. The 2025 version covered the ten drugs subject to Medicare price negotiation in 2026. The 2026 version adds the 2027 cohort, which roughly doubles the drug count and nearly doubles the manufacturer count. Covered entities got real operational protections that did not exist last year: a minimum submission window, a hard payment deadline, a requirement that denials come with stated reasons and documentation, a rule that manufacturers pay for the technology, and a mandatory 90-day implementation notice. HRSA also added a starting inventory grace period, allowing rebate requests for up to two unreplenished accumulated packages dispensed in the 15 days before go-live, which is a small kindness aimed at the neutral inventory replenishment problem that would otherwise strand product bought before January 1 under a discount regime and dispensed after it under a rebate regime.
